Status:
ACTIVE_NOT_RECRUITING
Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
Lead Sponsor:
University Hospital, Brest
Conditions:
Polycystic Kidney Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related compl...
Detailed Description
Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related compl...
Eligibility Criteria
Inclusion
- Patient with autosomal dominant polycystic kidney disease (APKD) participating in the Genkyst study
- Patient with at least one cystic complication. The cystic complications retained are the following:
- Acute or chronic cyst-related pain requiring analgesic treatments
- Cyst infection
- Intracystic haemorrhage
- Urinary lithiasis
- Functional complaints related to the cystic mass: digestive disorders with eating disorders, undernutrition, diaphragmatic compression phenomena, portal hypertension, umbilical or linea alba hernias, ventrations
- Need for a cystic reduction procedure: puncture, marsupialization, open surgery (including preparation for grafting)
Exclusion
- Patients who have expressed their opposition to taking part in the study
- Patient under legal protection (guardianship, curatorship, etc.)
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06036992
Start Date
October 1 2023
End Date
August 1 2027
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609